Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director comp.
Director departure
|
|
REVELATION BIOSCIENCES, INC.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/12/2023 |
8-K
| Quarterly results |
| 10/02/2023 |
8-K
| Quarterly results |
| 08/11/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023 San Diego, CA – August 11, 2023 – Revelation Biosciences Inc. , a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reported its three and six months ended June 30, 2023 financial results. Results of Operations As of June 30, 2023, Revelation had $15.7 million in cash and cash equivalents, compared to $5.3 million as of December 31, 2022. The increase in cash and cash equivalents was primarily due to net cash received from financing activities, offset primarily by cash used for operating activities. Based on current operating plans and projections, Revelation believes that its current cash and cash ..." |
|
| 08/11/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 07/14/2023 |
8-K
| Quarterly results |
| 07/07/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 06/29/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data|
Docs:
|
"REMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of Stockholders San Diego, CA – June 29, 2023 – Revelation Biosciences Inc. , a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reminded stockholders that the virtual Annual Meeting of Stockholders is scheduled for Friday, July 7, 2023, at 1:00 p.m. Eastern Time and urges all stockholders to vote now. YOUR VOTE IS IMPORTANT - NO MATTER HOW MANY SHARES YOU OWN, HOW FEW SHARES YOU OWN, OR IF YOU VOTE YOUR SHARES FOR, AGAINST OR ABSTAIN Important Information This communication may be deemed to be solicitation material in connection with the proposals to be considered at the Annual Meeting. In connection with..." |
|
| 06/12/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 05/25/2023 |
8-K
| Investor presentation |
| 04/03/2023 |
8-K
| Quarterly results |
| 02/13/2023 |
8-K
| Quarterly results |
| 01/31/2023 |
8-K
| Quarterly results |
| 01/10/2023 |
8-K
| Investor presentation |
| 01/10/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 12/21/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...|
Docs:
|
"REVELATION BIOSCIENCES, INC. CERTIFICATE OF DESIGNATION OF SERIES A PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Revelation Biosciences, Inc., a Delaware corporation , that the following resolution was duly adopted by the board of directors of the Corporation , in accordance with the provisions of Section 151 of the General Corporation Law of the State of Delaware, as amended on December 14, 2022, which resolution provides for the creation of a series of the Corporation’s Preferred Stock, par value $0.001 per share, which is designated as “Series A Preferred Stock,” with the rights, preferences, privileges and restrictions set forth therein. WHEREAS, the Third Amended and Rest...",
"Revelation Biosciences, Inc. Series A Preferred Stock SUBSCRIPTION AND INVESTMENT REPRESENTATION AGREEMENT THIS AGREEMENT, dated as of December 19, 2022, is by and between Revelation Biosciences, Inc., a Delaware corporation , and the undersigned subscriber . In consideration of the mutual promises contained herein, and other good, valuable and adequate consideration, the parties hereto agree as follows: 1. Agreement of Sale; Closing. The Company agrees to sell to Subscriber, and Subscriber agrees to purchase from the Company, one share of the Company’s Series A Preferred Stock, par value $0.001 per share , which Securities shall have the rights, preferences, privileges and restrictions set forth in the Certificate of Designation attached hereto as Exhibit A . Subscriber hereby acknowledge..." |
|
| 12/12/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 11/25/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 10/25/2022 |
8-K
| Quarterly results |
| 10/06/2022 |
8-K
| Quarterly results |
| 08/17/2022 |
8-K
| Quarterly results |
| 08/01/2022 |
8-K
| Quarterly results |
| 06/10/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 05/31/2022 |
8-K
| Quarterly results |
| 05/16/2022 |
8-K
| Quarterly results |
| 04/22/2022 |
8-K/A
| Financial Statements and Exhibits Interactive Data|
Docs:
|
"INDEX TO FINANCIAL STATEMENTS REVELATION BIOSCIENCES, INC. Report of Independent Registered Public Accounting Firm 2 Balance Sheets 3 Statements of Operations 4 Statements of Changes in Stockholders’ Equity 5 Statements of Cash Flows 6 Notes to the Financial Statements 7 1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Stockholders of Revelation Biosciences, Inc. Opinion on the Financial Statements We have audited the accompanying balance sheet of Revelation Biosciences, Inc. as of December 31, 2021 and 2020, the related statements of operations, changes in stockholders’ equity , and cash flows for the year ended December 31, 2021 and the period from May 4, 2020 to December 31, 2020, and the related notes to the financial statements . In our opinion, ...",
"MANAGEMENT’ S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS" |
|
| 04/15/2022 |
8-K/A
| Financial Statements and Exhibits Interactive Data|
Docs:
|
"INDEX TO FINANCIAL STATEMENTS REVELATION BIOSCIENCES, INC. Report of Independent Registered Public Accounting Firm 2 Balance Sheets 3 Statements of Operations 4 Statements of Changes in Stockholders’ Equity 5 Statements of Cash Flows 6 Notes to the Financial Statements 7 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Stockholders of Revelation Biosciences, Inc. Opinion on the Financial Statements We have audited the accompanying balance sheet of Revelation Biosciences, Inc. as of December 31, 2021 and 2020, the related statements of operations, changes in stockholders' equity , and cash flows for the year ended December 31, 2021 and the period from May 4, 2020 to December 31, 2020, and the related notes to the financial statements . In our opinion, th...",
"MANAGEMENT’ S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS" |
|
| 03/15/2022 |
8-K
| Quarterly results |
| 02/10/2022 |
8-K
| Investor presentation |
| 01/27/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...|
Docs:
|
"FORM OF UNREGISTERED PRE-FUNDED COMMON STOCK PURCHASE WARRANT",
"FORM OF UNREGISTERED COMMON STOCK PURCHASE WARRANT",
"FORM OF UNREGISTERED PLACEMENT AGENT WARRANT",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of January 23, 2022, between Revelation Biosciences, Inc., a Delaware corporation , and the purchaser identified on the signature page hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4 of the Securities Act , and Rule 506 promulgated thereunder, the Company desires to issue and sell to the Purchaser, and the Purchaser desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Purchaser agrees as follow...",
"Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement.",
"Revelation Biosciences Raises $7.76 Million in Equity Financing" |
|
| 01/14/2022 |
8-K
| Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Changes in Control of Registrant... |
| 01/13/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 01/12/2022 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 12/23/2021 |
8-K
| Quarterly results |
| 12/17/2021 |
8-K
| Quarterly results |
|
|
|